Contrasting Mosaic ImmunoEngineering (OTCMKTS:CPMV) and BeyondSpring (NASDAQ:BYSI)

Mosaic ImmunoEngineering (OTCMKTS:CPMV) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Insider & Institutional Ownership

40.3% of BeyondSpring shares are held by institutional investors. 81.0% of Mosaic ImmunoEngineering shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Volatility and Risk

Mosaic ImmunoEngineering has a beta of -0.82, suggesting that its stock price is 182% less volatile than the S&P 500. Comparatively, BeyondSpring has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Mosaic ImmunoEngineering and BeyondSpring, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mosaic ImmunoEngineering	0	0	0	0	0.00
BeyondSpring	1	0	0	0	1.00

Valuation & Earnings

This table compares Mosaic ImmunoEngineering and BeyondSpring”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mosaic ImmunoEngineering	N/A	N/A	-$920,000.00	($0.09)	-6.54
BeyondSpring	$1.75 million	39.06	-$11.12 million	($0.15)	-11.30

Mosaic ImmunoEngineering has higher earnings, but lower revenue than BeyondSpring. BeyondSpring is trading at a lower price-to-earnings ratio than Mosaic ImmunoEngineering, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Mosaic ImmunoEngineering and BeyondSpring’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Mosaic ImmunoEngineering	N/A	N/A	-761.65%
BeyondSpring	N/A	N/A	N/A

Summary

BeyondSpring beats Mosaic ImmunoEngineering on 5 of the 9 factors compared between the two stocks.

About Mosaic ImmunoEngineering

Mosaic ImmunoEngineering, Inc., a development-stage biotechnology company, focuses on developing and commercializing immunomodulator platform technology for the treatment of cancer and infectious diseases in humans and for veterinary use. Its lead immunotherapy product candidate, MIE-101, a nanoparticle-based treatment derived from cowpea mosaic virus, which is non-infectious in humans and animals. The company was founded in 2020 and is based in Novato, California.

About BeyondSpring

BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development of cancer therapies. The company's lead asset is the Plinabulin, a selective immunomodulating microtubule-binding agent that has completed Phase III clinical trials for treatment of non-small cell lung cancer (NSCLC); and as an anti-cancer agent, as well as for the prevention of chemotherapy-induced neutropenia. It is also developing Plinabulin in combination with docetaxel vs. docetaxel alone for the treatment of NSCLC and epidermal growth factor receptor wild type. In addition, the company develops Plinabulin in combination with various immuno-oncology agents and chemotherapy or radiation, including; nivolumab, a PD-1 antibody that is has completed phase 1 clinical trials for the treatment of non-small cell lung cancer; ipilimumab, a CTLA-4 antibody for the treatment of extensive-stage small cell lung cancer; in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers; and pembrolizumab, etoposide, and platinum to treat extensive-stage small cell lung cancer. Further, it engages in the development of three small molecule immune agents in preclinical stages; and a drug discovery platform to develop therapeutic agents from internal research and development efforts and from collaboration. The company was founded in 2010 and is headquartered in Florham Park, New Jersey.